NCT03245151: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 21 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Breast cancer patients are only eligible for Phase 1
Exclusions: Patients that are not between the ages of 2-21; Evidence of untreated CNS metastases
https://ClinicalTrials.gov/show/NCT03245151

Comments are closed.

Up ↑